stockrow
Friday 6 November 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
- Revenue
- +23.9%
- EPS
- −550.0%
- Free cash flow
- +56.8%
- Total debt
- −59.9%
Quarter to September 2026, against a year earlier
32.65
1.55
−4.53%
Follow CSTL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.28 | 2.16 | 2.03 | 2.89 | |
P/FCF ratio |
39.74 | 160.88 | 0.00 | 272.85 | |
P/Operating CF |
41.87 | (33.16) | 47.70 | 55.13 | |
P/B ratio |
2.39 | 1.59 | 1.54 | 2.27 | |
Price to Tangible BV |
3.04 | 2.02 | 1.93 | 2.81 | |
EV/Sales |
2.44 | 1.42 | 1.31 | 2.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
13.03 | 10.00 | 10.99 | 20.96 | |
EV/FCF |
29.55 | 105.78 | (1,036.62) | 208.87 | |
Quick Ratio |
4.99 | 6.23 | 5.58 | 0.77 | |
Current Ratio |
5.26 | 6.75 | 6.04 | 5.28 | |
Net Debt/EBITDA |
381.44 | 16.83 | (421.82) | 3.77 | |
Debt/Assets |
1.79% | 1.89% | 1.84% | 0.72% | |
Debt/Equity |
0.02 | 0.02 | 0.02 | 0.01 | |
Asset Turnover |
0.62 | 0.65 | 0.65 | 0.66 | |
Operating CF/Net income |
(11.55) | 1.52 | (7.38) | (4.81) | |
Capex/Depreciation |
(2.34) | (3.58) | (2.35) | (1.95) | |
Interest Coverage |
(159.46) | (137.37) | (15.91) | (13.86) | |
Research and Development Expense of Revenue |
15.53% | 17.24% | 14.04% | 15.36% | |
Selling, General and Administrative Expense of Revenue |
65.20% | 77.56% | 63.86% | 62.00% | |
Intangible Assets out of Total Assets |
0.17 | 0.18 | 0.17 | 0.16 | |
Share Based Compensation of Revenue |
13.11% | 11.68% | 11.19% | 10.92% | |
Graham Net Nets |
0.22 | 0.33 | 0.34 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.16%) | (1.75%) | (2.77%) | (2.17%) | |
Free Cash Flow Yield |
2.52% | 0.62% | (0.06%) | 0.37% | |
Revenue per Share |
3.00 | 2.80 | 3.41 | 3.36 | |
Operating CF per Share |
0.93 | (0.74) | 0.50 | 0.64 | |
Capex per Share |
(0.25) | (0.42) | (0.28) | (0.24) | |
Free Cash Flow per Share |
0.68 | (1.16) | 0.22 | 0.40 | |
Cash per Share |
10.33 | 8.76 | 8.78 | 0.00 | |
Shareholders Equity per Share |
16.24 | 15.44 | 15.46 | 15.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.24 | 15.44 | 15.46 | 15.62 | |
Free Cash Flow |
19.75 | (34.58) | 6.56 | 12.26 | |
Working Capital |
292.42 | 280.14 | 284.59 | 289.25 | |
Capital Expenditures |
(7.18) | (12.45) | (8.64) | (7.48) | |
Net Current Asset Value |
253.41 | 242.51 | 249.95 | 255.89 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.15 | 0.08 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
47.30 | 49.31 | 50.33 | 50.79 | |
Average Payables |
12.81 | 11.77 | 11.42 | 12.72 | |
Average Inventory |
9.19 | 8.66 | 9.47 | 9.52 | |
Average Assets |
554.90 | 524.76 | 552.95 | 571.10 | |
Average Common Equity |
463.35 | 450.86 | 462.70 | 472.75 |
Columns are period end dates · fundamentals updated 5 Nov 2026